The hallmarks of aging · The body's responses

Nutrient sensing

Scientific name: Deregulated nutrient sensing

Cells constantly sense how much food and energy is available, then choose between growing and repairing. With age these sensors drift toward growth: growth signals stay high, the low-fuel signal weakens, and repair work falls behind.

Measurable today: indirectly, with common blood tests such as fasting glucose and insulin.

Why it matters

Why it matters to you

Turning growth signals down extends life in animals.

Eating less extends lifespan in many animals. A drug that blocks the main growth switch, mTOR, extended lifespan in mice even when started late in life.

Source: PubMed 19587680

It is the driver ordinary blood tests come closest to.

Fasting glucose, insulin, and long-term blood sugar show how well your body handles fuel. They read these switches only indirectly, but they are cheap and widely available.

Less is not always better.

Growth signals also build muscle and help healing. In older adults, too little protein or too much restriction can speed muscle loss, so the goal is balance, not shutting growth off.

Measurement

Can it be measured?

Fasting glucose, insulin, and HbA1c

Standard blood tests

What it showsHow well your body keeps blood sugar steady and how hard insulin has to work to do it.

LimitsThey read the system indirectly, and their ranges were set to flag diabetes risk, not aging. There are no agreed targets for healthy aging.

Blood NAD+ test

Sold to consumers

What it showsThe level of NAD+, a molecule cells use to handle fuel, in a blood sample.

LimitsAcross seven groups of people, whole-blood NAD+ stayed stable with age and with lifestyle changes. It rose only with an NAD+ precursor supplement, so it is a poor gauge of aging.

Sources: PubMed 42135539

Continuous glucose monitor

Sold to consumers

What it showsBlood sugar minute by minute, including spikes after meals.

LimitsIt was built and validated for diabetes. Targets for healthy people who want to age well have not been established.

What would make it measurable

  • Blood tests that read the growth and repair switches directly, not only blood sugar.
  • Agreed targets for healthy aging, not only for diabetes.
  • Results from large human trials now testing drugs that act on these switches.
What can be done

What can be done about it?

Sixteen items in our catalog have human studies that support an effect on these food-sensing switches, and they push in different directions. Some mimic a low-fuel signal, such as aerobic exercise, metformin, and berberine. Others turn growth signals up, such as resistance training, whey protein, and growth hormone. Which direction helps depends on age and health, and no product has been shown to slow aging in people this way.

Three examples from our catalog, rotated daily: one with stronger evidence here, one with early evidence, and one where we found none. A sample, not a ranking or a recommendation. Ratings as of October 25, 2026. What the evidence levels mean.

Exercise & lifestyle

Resistance training

Evidence for nutrient sensing: Strong

Strong human evidence that it engages this aging driver.

Gut & Fiber

Resistant Starch

Evidence for nutrient sensing: Emerging

Only early or animal-stage evidence for this aging driver so far.

Mushroom

Reishi Mushroom Extract

Evidence for nutrient sensing: None found

We did not find qualifying evidence that it engages this aging driver.

Its stronger evidence is for DNA damage and disrupted cell signaling.

See the full picture for your own routine

The Longevity Intelligence Report shows how what you take and do covers nutrient sensing and the other hallmarks. Members also see every item in our catalog ranked by the strength of its evidence for nutrient sensing. Opens in December.

Get early access
New research

New studies on nutrient sensing

Picked for what they add to the biology, and to the chance of one day treating it, in plain words. Research checked October 17, 2026.

Nutrient sensing

A GLP-1 drug started late in life extended lifespan in female mice

Mice · Nature · September 2, 2026

What they foundOld female mice given semaglutide did better on physical, memory, and blood-sugar tests. Mice kept on it had a median lifespan about 12 percent longer, with many changes resembling calorie restriction.

What it does not showFemale mice only. It does not show the drug slows aging in people.

Why it mattersIt is a lifespan result for a drug millions of people already take, tied to the same nutrient-sensing systems calorie restriction works through.

Read the study on PubMed ↗
Late-life semaglutide treatment slows ageing and extends lifespan in female mice.
Nutrient sensing

Eating within a set window extended healthspan in mice, and lifespan in males only

Mice, 528 animals on a regular diet · Nature Aging · June 2, 2026

What they foundMice fed only during a nightly 8- or 12-hour window were leaner and less frail, with later disease onset. The 8-hour mice also ate less on their own. Their median lifespan rose 12 percent in males, with no significant change in females.

What it does not showMice only. The 8-hour group also ate fewer calories, so meal timing and eating less are hard to separate.

Why it mattersIt is one of the largest long-term tests of meal timing in mammals, and it shows the effect can differ by sex.

Read the study on PubMed ↗
Time-restricted feeding extends healthspan in both sexes and lifespan in male C57BL/6 J mice.
Nutrient sensing

Two years of eating less calmed an inflammation pathway in people

People in a 2-year calorie-restriction trial, plus mice · Nature Aging · April 13, 2026

What they foundAdults who cut calories by about 14 percent for two years had lower activity in part of the immune defense called complement, which tracked lower age-related inflammation. In mice, blocking one complement signal in belly fat reduced that inflammation.

What it does not showThese are blood markers, not health outcomes, and the mouse treatment has not been tested in people.

Why it mattersIt shows one concrete way eating less may slow aging biology in humans: by turning down a source of chronic inflammation.

Read the study on PubMed ↗
Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging.

Follow the research on nutrient sensing

Pick the ones you want to follow. Starting in December, we'll email you every two weeks when new studies or new tests come out on them. Longevity Intelligence Report members also get the plain-English read on each one: why it matters, and whether it should change what you're doing.

Free, no account needed. We keep your email and the topics you pick, nothing else. Unsubscribe anytime.

From the articles

Articles on nutrient sensing

Go deeper

Connected hallmarks

How the biology works

Insulin and IGF-1 are the body's fed and grow signal. Insulin is the hormone released when you eat, telling cells to pull sugar out of the blood and store it, while IGF-1 (insulin-like growth factor 1, a growth hormone closely related to insulin) tells cells to grow and divide. Both work through the same downstream chain, the PI3K-AKT route, that pushes cells toward building and storing rather than recycling. When meals are frequent and large for years, cells are flooded with this signal so often that they start ignoring it, which is insulin resistance: the body has to shout louder (release more and more insulin) to get the same effect, and chronically high insulin is itself a growth-promoting, pro-aging signal.

mTOR is the master growth switch that senses abundance. mTOR (mechanistic target of rapamycin, a central control protein named after the drug that blocks it) reads the supply of amino acids, the building blocks from dietary protein, and of energy and insulin signaling. When fuel and protein are plentiful, mTOR switches on and the cell pours its resources into making new proteins and growing, and it deliberately suppresses autophagy, the cell's recycling and self-cleaning process. That is exactly what you want during growth and after exercise. The problem is chronic activation: if mTOR almost never gets the chance to switch off, the cleanup that should happen during the fasted state rarely runs, and damaged components accumulate.

AMPK is the opposite sensor, the one that fires when fuel runs low. AMPK (AMP-activated protein kinase, an energy gauge) switches on when the cell's energy charge drops, during fasting, exercise, or calorie restriction. When it fires it does the reverse of mTOR: it suppresses growth, switches on autophagy, prompts the cell to build new mitochondria (the power plants), and shifts the body toward burning stored fat. AMPK and mTOR sit on opposite ends of the same seesaw, and a youthful metabolism tips cleanly back and forth between them across the day; an aging, always-fed metabolism gets stuck with the seesaw pinned to the mTOR side.

Sirtuins are the fourth sensor and they run on a coenzyme that falls with age. Sirtuins are a family of enzymes (SIRT1 through SIRT7) that promote stress resistance, support mitochondrial health, help repair DNA, and help keep the epigenome correctly set. They depend on NAD+ (nicotinamide adenine dinucleotide, a helper molecule central to energy metabolism), and because NAD+ levels decline with age, sirtuin activity tends to fade too, weakening this whole repair-favoring arm just as the growth arm is overactive.

The four systems share one job: the growth-versus-maintenance tradeoff. A cell cannot maximize growth and maximize repair at the same time, because the resources and the molecular machinery overlap, so it has to choose moment to moment. Insulin/IGF-1 and mTOR vote for growth and storage; AMPK and sirtuins vote for maintenance and recycling. This is why the same hallmark can be protective and harmful: the growth vote is correct when you are young, healing, or building muscle, and the maintenance vote is correct when you are fasted or under stress. Aging is less about one vote being wrong and more about the balance getting frozen on the growth side.

The levers that move this balance are mostly behavioral, which is why this hallmark is so modifiable. Calorie restriction, periods of fasting or time-restricted eating, exercise, and lower refined-carbohydrate intake all lower insulin and mTOR and raise AMPK and sirtuin activity, shifting the body back toward repair. Dietary protein is the trickiest input, because it raises mTOR (which you want for building muscle) while the longevity literature often prizes lower mTOR, which is a real tension rather than a settled answer. These are the same biological switches that caloric-restriction research in animals has been pulling for decades.

Metabolic inflexibility is the visible endpoint. A healthy metabolism switches fuel sources easily, burning sugar after a meal and fat between meals, and the rapid back-and-forth between the growth and repair sensors is what makes that switch clean. With chronic overfeeding and insulin resistance the body loses this flexibility, getting stuck half-burning both fuels inefficiently, which is the practical, whole-body face of deregulated nutrient sensing and a common thread linking it to type 2 diabetes, fatty liver, and cardiovascular disease.

Where treatment research is heading
Next few years

Rapamycin and rapalogs at low intermittent doses for healthspan

Rapamycin, the drug mTOR is named after, extends lifespan across yeast, worms, flies, and mice more reproducibly than almost any other compound, and low intermittent dosing in humans (including the rapalog everolimus, which improved immune response to vaccination in older adults) is now in dedicated aging trials. It is the closest thing the field has to a direct nutrient-sensing intervention with deep animal support.

Not ready yet: The right human dose and schedule that capture the benefit without immune suppression, poor wound healing, or metabolic side effects are not established, and long-term safety in healthy people is unproven.

Metformin and the TAME-style trials

Metformin, a widely used and inexpensive diabetes drug that nudges AMPK on and dampens excess growth signaling, is the basis of the proposed Targeting Aging with Metformin (TAME) trial, the first major attempt to test whether a drug can slow aging itself as a regulatory endpoint, which would change how the entire field is studied.

Not ready yet: Evidence in people who do not have diabetes is mixed, some studies suggest it may blunt the muscle and fitness gains from exercise, and the landmark trial is still seeking full funding, so benefit in healthy adults remains unconfirmed.

GLP-1 receptor agonists and time-restricted eating

GLP-1 receptor agonists (the semaglutide and tirzepatide class) dramatically improve insulin sensitivity, blood sugar, and weight, directly easing the chronic-overfeeding state that deregulates nutrient sensing, while time-restricted eating lowers insulin and lets mTOR switch off long enough for repair to run, a low-risk lever available today.

Not ready yet: GLP-1 drugs are proven for metabolic disease and weight, not yet for slowing aging in metabolically healthy people, and can cause muscle loss without resistance training; for time-restricted eating, the long-term aging outcomes (as opposed to weight and glucose) are not established and extreme schedules carry their own risks.

Further out

Tissue-selective mTOR modulators

The next generation aims to dial mTOR down only in the tissues where chronic activation is harmful while sparing the muscle and immune cells that need it, potentially capturing the longevity upside of mTOR inhibition without the side effects that limit rapamycin today.

Not ready yet: mTOR sits at the center of normal growth, immunity, and metabolism in every tissue, so achieving genuinely tissue-selective control without disrupting essential functions is unsolved, and these candidates are early.

NAD-axis and sirtuin-activator approaches

Because sirtuins run on NAD+, a coenzyme that falls with age, compounds that raise NAD+ (including nicotinamide riboside and NMN) or directly activate sirtuins aim to restore the repair-favoring arm of nutrient sensing, supporting mitochondrial health, DNA repair, and epigenetic maintenance at once.

Not ready yet: Human evidence that raising NAD+ or activating sirtuins meaningfully improves aging outcomes is early and inconsistent, sirtuin biology turned out more tangled than the initial excitement suggested, and a marker change is not a proven health benefit.

Long shots

Precise nutrient-sensing reprogramming for caloric-restriction benefits without the downsides

The far-horizon goal is to selectively engage only the protective, repair-favoring side of nutrient sensing, capturing the well-documented benefits of caloric restriction and fasting while sparing the muscle, immune, and growth functions that legitimately depend on these same pathways, in effect getting the upside of eating less without the cost of losing strength or immune defense.

Not ready yet: These four sensing systems are deeply interwoven with normal growth, immunity, fertility, and metabolism in every tissue, the protective and harmful effects often run through the very same molecules, and we do not have the precision to separate them safely, so clean targeting remains out of reach.

Facts and sources on this page checked October 17, 2026. This page explains research. It is not medical advice or a recommendation to take anything. How we grade the evidence.